Select Premarket Movers

Avatar photo Doug Kass on October 14, 2026

Upside

– $LQDA +41.0% ($380.7M global settlement resolves six lawsuits and preserves uninterrupted YUTREPIA commercialization)

– $TCRT +25.5% (completed Velaris acquisition and secured an approximately $350M private placement to fund development through 2029)

– $VSTM +11.0% (VS-7375 produced a 50% confirmed response rate in eight second-line pancreatic-cancer patients, with FDA alignment on a Phase 3 plan)

– $ENVX +10.0% (received a 100,000-battery drone order and reported preliminary Q3 revenue above guidance)

– $BLK +5.0% (Q3 beat as $205B of net inflows and strong organic base-fee growth topped expectations)

– $ACN +4.0% (investor day targets)

Downside

– $BMEA -20.0% (Phase 1 BMF-650 weight-loss data disappointed investors despite no severe or serious treatment-emergent events)

– $STT -8.5% (Q3 EPS was roughly in line, but revenue missed and fee revenue declined sequentially)

– $FAST -4.5% (Q3 revenue came in slightly light and the 2026 device-signings target was trimmed despite an EPS beat and better operating margin)

– $BAC -4.5% (Q3 adjusted EPS and revenue missed as a $1.2B regulatory-settlement charge weighed on results)

– $HPE -4.5%, NTAP -4.0%, DELL -3.0% (Barclays downgrades the hardware names to Equal Weight, citing valuation and a lack of meaningful AI-driven growth inflection)

– $CRWV -4.0% (no clear fresh company-specific catalyst identified; unusually large premarket move)

Position: None

Upside, Downside Movers in the Morning

Avatar photo Doug Kass on September 23, 2026

Source: TradeTheNews

Upside

– $VTGN +59.5% (extends the prior-session rally after preliminary PALISADE-4 open-label extension data for fasedienol in social anxiety disorder)

– $GRML +24.0% (no clear fresh catalyst identified; exceptionally heavy-volume small-cap move)

– $WOR +15.5% (Q1 beat as stronger Building Products results and data-center demand lifted performance)

– $TLSI +15.0% (FDA grants 510(k) clearance for the TriNav Advance drug-delivery device)

– $IONQ +13.0% (demonstrates an end-to-end real-time quantum error-correction decoder running on a standard CPU)

– $CBRL +9.0% (Q4 profit beat and FY27 EBITDA outlook pointed to a sharp recovery despite lower sales)

– $QUBT +4.0% (quantum-computing sympathy following IONQ’s error-correction milestone)

– $CART +3.0% (expands its AI-shopping partnership network)

– $APH +3.0% (Bernstein initiates coverage at Outperform)

Downside

– $JAGX -48.0% (reverses sharply after the prior session’s roughly twelvefold FDA-fee-waiver-driven surge)

– $INNV -8.5% (10M-share secondary offering by selling stockholders creates a near-term stock overhang)

– $VOYG -7.5% ($350M convertible-senior-notes offering raises dilution concerns)

– $ASTH -7.5% (no clear fresh catalyst identified; renewed selling follows the recent short report questioning accounting estimates)

– $BMEA -7.0% (launches an underwritten common-stock and pre-funded-warrant offering)

– $AU -4.5%, GFI -4.5%, AG -3.0%, NEM -2.0% (precious-metals miners fall as gold and silver prices retreat)

– $BABA -3.0% (China ADR weakness ahead of the U.S.-China summit as mainland equities decline)

– $APP -2.5% (extends the AI-disruption selloff on concern consumer agents could pressure ad-tech economics)